Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Merck & Co., Inc. opera como una empresa de atención médica en todo el mundo. Ofrece productos farmacéuticos para la salud humana para diversas áreas bajo Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre, Lagevrio, Marcas Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia y Janumet.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $66.4B | $64.9B | $64.2B | $60.1B | $59.3B | $48.7B | $41.5B | $39.1B | $42.3B | $40.1B | $39.8B | $39.5B | $42.2B | $44.0B | $47.3B | $48.0B | $46.0B | $27.4B | $23.9B | $24.2B | $22.6B |
| Beneficio bruto | $50.0B | $46.7B | $49.0B | $44.0B | $41.9B | $35.1B | $27.9B | $27.1B | $28.8B | $27.2B | $25.8B | $24.6B | $25.5B | $27.1B | $30.8B | $31.2B | $27.6B | $18.4B | $18.3B | $18.1B | $16.6B |
| % de margen bruto | 75.4% | 72.0% | 76.3% | 73.2% | 70.6% | 72.0% | 67.2% | 69.3% | 68.1% | 67.8% | 64.8% | 62.2% | 60.3% | 61.5% | 65.2% | 64.9% | 60.0% | 67.1% | 76.6% | 74.6% | 73.5% |
| Ingresos operativos (EBIT) | $11.3B | $23.5B | $20.2B | $3.0B | $18.3B | $13.2B | $5.5B | $7.9B | $8.9B | $6.8B | $5.5B | $7.5B | $6.7B | $7.7B | $9.9B | $9.0B | $3.4B | $4.0B | $6.1B | $5.6B | $3.7B |
| % de margen operativo | 17.0% | 36.2% | 31.5% | 4.9% | 30.8% | 27.1% | 13.4% | 20.3% | 21.1% | 16.9% | 13.8% | 19.1% | 15.8% | 17.4% | 20.9% | 18.7% | 7.3% | 14.7% | 25.5% | 23.2% | 16.3% |
| Ingresos netos | $3.2B | $18.3B | $17.1B | $365M | $14.5B | $13.0B | $7.1B | $9.8B | $6.2B | $2.4B | $3.9B | $4.4B | $11.9B | $4.4B | $6.2B | $6.3B | $861M | $12.9B | $7.8B | $3.3B | $4.4B |
| % de margen neto | 4.8% | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | 17.0% | 25.2% | 14.7% | 6.0% | 9.8% | 11.2% | 28.2% | 10.0% | 13.1% | 13.1% | 1.9% | 47.0% | 32.7% | 13.5% | 19.6% |
| EBITDA | $12.0B | $28.3B | $25.7B | $6.9B | $21.3B | $17.9B | $10.2B | $11.4B | $14.0B | $12.0B | $10.8B | $12.4B | $24.7B | $13.3B | $16.4B | $15.5B | $9.7B | $18.3B | $11.8B | $7.6B | $6.0B |
| Beneficio por acción (EPS) | $1.25 | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 | $2.78 | $3.82 | $2.32 | $0.87 | $1.41 | $1.56 | $4.07 | $1.47 | $2.01 | $2.03 | $0.28 | $5.67 | $3.64 | $1.49 | $2.03 |
| Acciones en circulación (M) | 2,472M | 2,507M | 2,541M | 2,547M | 2,542M | 2,538M | 2,541M | 2,580M | 2,679M | 2,748M | 2,787M | 2,841M | 2,928M | 2,996M | 3,076M | 3,094M | 3,120M | 2,273M | 2,143M | 2,193M | 2,188M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de MRK. /companies/us/MRK
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms